Cytokinetics should hear back from the FDA next September about its marketing application for aficamten, which is vying to become the first rival to Bristol-Myers Squibb's fast-growing Camzyos for ...

Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...

NORWALK, CT , Feb. 11, 2026 (GLOBE NEWSWIRE) -- HCM IV Acquisition Corp (the “Company”), a blank check company whose business purpose is to effect a merger, amalgamation, share exchange, asset ...

Septal myectomy removes part of a thickened septum to treat hypertrophic cardiomyopathy (HCM) with left ventricular outflow tract obstruction. It can improve severe symptoms that do not respond to ...

Learn how to use and get the most from Google Docs, Sheets, Slides, Meet, Keep, Forms, Gmail, and other apps in Google’s Workspace productivity suite. From its humble origins as a collection of cloud ...

Minecraft remains one of the best games of all time over a decade on from its release, but spending such a long time in one game could lead to you running out of ideas. We've been there: you've ...

Find the latest HCM Defender 100 Index ETF (QQH) stock quote, history, news and other vital information to help you with your stock trading and investing.

Copyright © 2026 Insider Inc and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service ...

HCM III Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.

Mavacamten did not significantly improve exercise capacity as assessed by peak oxygen uptake or improve patient-reported health status compared with placebo in patients with symptomatic nonobstructive ...

Aficamten monotherapy was superior to metoprolol monotherapy in improving peak oxygen uptake and hemodynamics and decreasing symptoms among patients with symptomatic obstructive hypertrophic ...